Geron Files 8-K on Financial Condition & Reg FD Disclosure

Ticker: GERN · Form: 8-K · Filed: Jan 8, 2024 · CIK: 886744

Geron Corp 8-K Filing Summary
FieldDetail
CompanyGeron Corp (GERN)
Form Type8-K
Filed DateJan 8, 2024
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.001, $376.9 million
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: financial-condition, regulation-fd, corporate-disclosure

TL;DR

**Geron just dropped an 8-K about its financials and Reg FD, get ready for potential news.**

AI Summary

Geron Corporation filed an 8-K on January 8, 2024, to disclose information under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). This filing indicates that Geron is providing an update on its financial condition and operations, likely related to an upcoming event or announcement. For investors, this matters because it signals that new, potentially market-moving financial information is being made public, which could influence the stock price of GERN.

Why It Matters

This filing signals that Geron Corporation is releasing new financial information, which could impact investor perception and the company's stock performance. Investors should pay close attention to the specific details of the financial condition and Regulation FD disclosures.

Risk Assessment

Risk Level: medium — The risk is medium because while the filing itself is administrative, the underlying financial disclosures could contain positive or negative news, creating uncertainty.

Analyst Insight

A smart investor would immediately look for the full content of the 8-K to understand the specific financial results and Regulation FD disclosures, as these details will determine the actual impact on Geron's stock price.

Key Players & Entities

  • GERON CORPORATION (company) — the registrant filing the 8-K
  • January 08, 2024 (date) — date of earliest event reported and filing date
  • 000-20859 (string) — Commission File Number
  • 75-2287752 (string) — IRS Employer Identification No.
  • 919 E. HILLSDALE BLVD., SUITE 250 FOSTER CITY, CALIFORNIA 94404 (string) — Address of principal executive offices
  • 650-473-7700 (string) — Registrant’s telephone number
  • GERN (string) — Trading Symbol for Common Stock
  • The Nasdaq Stock Market LLC (string) — Exchange where Common Stock is registered

FAQ

What specific items did Geron Corporation report on in this 8-K filing?

Geron Corporation reported on Item 2.02, 'Results of Operations and Financial Condition,' and Item 7.01, 'Regulation FD Disclosure,' as indicated in the 'ITEM INFORMATION' section of the filing.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 08, 2024, as stated under 'Date of Report (Date of earliest event reported): January 08, 2024'.

What is Geron Corporation's trading symbol and on which exchange is its common stock registered?

Geron Corporation's trading symbol is GERN, and its Common Stock, $0.001 par value, is registered on The Nasdaq Stock Market LLC, according to the 'Securities registered pursuant to Section 12(b) of the Act' section.

What is the business address and phone number of Geron Corporation?

Geron Corporation's business address is 919 E. HILLSDALE BLVD., SUITE 250 FOSTER CITY, CALIFORNIA 94404, and its telephone number is (650) 473-7700, as listed in the filing.

What is the purpose of an Item 7.01 Regulation FD Disclosure in an 8-K filing?

An Item 7.01 Regulation FD Disclosure is used to make public any material nonpublic information that a company has selectively disclosed to certain individuals, ensuring that all investors receive the information simultaneously to prevent unfair advantage, as per the SEC's Regulation FD.

Filing Stats: 776 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2024-01-08 08:25:16

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value GERN The Nasdaq Stock Mar
  • $376.9 million — marketable securities of approximately $376.9 million. The aforementioned financial informati

Filing Documents

02

Item 2.02 Results of Operations and Financial Condition. Geron Corporation (the “Company” or “Geron”) will participate in various meetings with securities analysts and investors during the 42 nd Annual J.P. Morgan Healthcare Conference the week of January 8, 2024, and will utilize a presentation handout during those meetings. Such presentation handout discloses that Geron expects to report that, as of December 31, 2023, it had cash, cash equivalents, restricted cash and current and non-current marketable securities of approximately $376.9 million. The aforementioned financial information is included on slide #30 of the presentation handout, as furnished in Exhibit 99.1 to this Current Report, and is incorporated herein by reference. The Company has not yet completed its financial close process for the quarter and year ended December 31, 2023. This estimate of the Company’s cash, cash equivalents, restricted cash and current and noncurrent marketable securities as of December 31, 2023, is preliminary, unaudited and is subject to change upon completion of the Company’s financial statement closing procedures and the audit of the Company’s consolidated financial statements.

01

Item 7.01 Regulation FD Disclosure. Geron will participate in various meetings with securities analysts and investors during the 42 nd Annual J.P. Morgan Healthcare Conference the week of January 8, 2024, and will utilize a presentation handout during those meetings. The presentation handout, together with a slide setting forth certain cautionary language intended to qualify the forward-looking statements included in the presentation handout, is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The presentation handout will also be made available in the Investors section of Geron’s website, located at www.geron.com. The information contained in Items 2.02 and 7.01 and in the accompanying Exhibit 99.1 to this Current Report shall be deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act, and shall not be incorporated by reference into any filing made by the Company with the U.S. Securities and Exchange Commission under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 January 2024 Corporate Presentation 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GERON CORPORATION Date: January 8, 2024 By: /s/ Scott A. Samuels Name: Scott A. Samuels Title: Executive Vice President, Chief Legal Officer and Corporate Secretary 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.